In part because of its resistance to many antibiotics, tuberculosis kills approximately 1.7 million people worldwide each year. But new research from the University of Notre Dame suggests that structures released by the infected cells may be used in tandem with antibiotics to boost the body’s immune system, helping fight off the disease.
The paper, published in EMBO Reports by Jeffrey Schorey, the George B. Craig Jr. Professor, and Yong Cheng, research assistant professor, both in the Department of Biological Sciences, describes how the structures, called extracellular vesicles (EVs), contain Mycobacterium tuberculosis RNA and transfer it to other cells. This starts a built-in weapon system against the disease in the form of an immune response.
Though extracellular vesicles containing RNA from viruses had been discovered years ago, Schorey and his collaborators recently discovered RNA from bacteria — Mycobacterium tuberculosis — in EVs. This discovery led to experiments described in the EMBO Reports paper to determine how the bacteria’s RNA was affecting the “target” cell, including cells infected by M. tuberculosis.
A key research discovery hinges on macrophages, which are cells of the immune system. These cells, when treated with EVs released from M. tuberculosis-infected cells, can control the infection better than macrophages not previously exposed to the EVs, Schorey and Cheng determined. “It had never before been shown that bacterial RNA in EVs can activate this sensing pathway, one that has primarily been thought to be involved in viral sensing,” Schorey said. The authors then show that EV-treated macrophages produce compounds like reactive oxygen species that can promote the killing of the M. tuberculosis once it infects the macrophage.
The discovery is important because it can lead to future therapies for treatment of tuberculosis. Preliminary data in the paper suggest that antibiotics might work better when combined with an immunotherapy based on using these EVs. The data from the mouse model showed that more of the bacterial-infected cells were killed with the combination of therapies than either antibiotics or EVs alone, Schorey noted.
The next steps for future research are to try this approach with other laboratory models, with the goal that they also show the benefit of combining EVs, as immunotherapy treatments, with antibiotics to treat drug-resistant tuberculosis.
Worldwide, more than 10 million people develop active tuberculosis each year. Furthermore, over two billion people are infected with the bacteria. This results in a reservoir of infected people who may develop disease if their immune systems are compromised.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Private Road Ambulance Services in Patna Saved the life of Tuberculosis Patienton January 24, 2021 at 3:40 am
We all know the sound of sirens screaming behind us, and we all recognize the red and blue lights flashing in harmony, letting us know that emergency vehicles are approaching and we must be vigilant.
- Tuberculosis Drugs Market Share 2021 Explosive Growth Analysis, Market Size, Trends, Top Manufacturers and Forecasts to 2025on January 20, 2021 at 5:35 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Tuberculosis Drugs Market” ...
- Tuberculosis screening to be carried out for Singapore Pools Bedok Betting Centre patrons after 2 clusters foundon January 20, 2021 at 3:02 am
The two separate clusters involve a total of 18 people, who frequently visited the Bedok centre over periods ranging from months to years.. Read more at straitstimes.com.
- Precautionary tuberculosis screening for some Singapore Pools Bedok Betting Centre patrons after 18 cases detected: MOHon January 20, 2021 at 1:49 am
Precautionary tuberculosis screening will be conducted for certain patrons of Singapore Pools Bedok Betting Centre after 18 cases were ...
- Proposing a new drug to treat tuberculosis utilizing state-of-the-art computer simulationson January 17, 2021 at 9:00 pm
In silico drug design for inhibiting the cell division of Mycobacterium tuberculosis and suppressing its growth based on high-precision molecular simulations The research team of the Department of ...
- Tuberculosis has vaccine lessons for Covidon January 17, 2021 at 6:57 pm
In the early 1900s, one of the leading causes of death in places like the UK was a lung disease called tuberculosis (TB). What has happened since is an important warning for how the world should be ...
- Tuberculosis kills as many people each year as COVID-19. It's time we found a better vaccineon January 15, 2021 at 6:22 am
In July 1921, a French infant became the first person to receive an experimental vaccine against tuberculosis (TB), after the mother had died from the disease. The vaccine, known as Bacille ...
- Prescription for tuberculosis a century ago? A shot of Harrisburg’s fresh air | Columnon January 15, 2021 at 5:55 am
Efforts in central Pennsylvania to prevent deadly tuberculosis in children included an open-air school, which got a bit chilly in winter, and a summer camp that offered plenty of relaxation.
- Sea lion diagnosed with tuberculosis triggers public health concernson January 14, 2021 at 6:30 am
Australian sea lions are an endangered species. New research suggests endemic tuberculosis might be another health threat facing the pinnipeds. Dr. Rachael Gray is working to help save our sea lions.
- Covid-19 impact: Tuberculosis Treatment Drugs Market to grow at a much faster rate beyond 2020| Financial Analysis and Forecaston January 13, 2021 at 10:48 pm
Market.Biz :Tuberculosis Treatment Drugs Businesses must navigate the financial and operational challenges of coronavirus while rapidly addressing the needs of their people, customers, and suppliers.
via Bing News